Document Type

Article

Publication Date

10-2014

Keywords

fsc2015

Abstract

Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of Pain Management has released a position statement on this medication, and individual opinion varies. Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER's limited clinical utility may make the controversy associated with its approval a moot point. As with other opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.

DOI

10.1177/1060028014543174

Comments

The final published version of this article is available through SAGE Journals: http://dx.doi.org/10.1177/1060028014543174

Share

COinS